LifeSci Capital Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $40
Eloxx Pharmaceuticals Inc ELOX
$17.43
▲ +31.05%
(+$4.13)
⬆️ Above Yest. High
🎈 Low Float
📅 Earnings This Week
Open
$13.90
Prev Close
$13.30
Day Range
$13.79 – $18.42
52W Range
$0.00 – $18.42
Market Cap
$730,974
Beta
3.41
EPS (TTM)
$-7.06
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | OTC MARKETS |
| Currency | USD |
| IPO Date | 2012-11-23 |
| Shares Out. | 4,040,000 |
| Website | eloxxpharma.com/ ↗ |
| Phone | 13026365400 |
| Employees | 7 |
| Net Income | -$3.8M |
| Total Assets | $8.5M |
| Total Liabilities | $16.1M |
| Equity | -$7.6M |
About Eloxx Pharmaceuticals Inc
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Eloxx Pharmaceuticals Inc is a publicly traded company under the ticker symbol ELOX on the OTC MARKETS, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2024-09-01)